Specific features of Brodie’s tumors
https://doi.org/10.17650/1994-4098-2010-0-3-21-23
Abstract
Brodie’s tumors are comparatively rare in oncological care and difficult-to-diagnose masses with an unpredictable course, predilection for recurrences, and a high probability of malignization. These tumors have a two-component structure with the predominant develop- ment of a connective tissue component that is absolute in sarcomas and, in a group of fibroepithelial tumors, combines with the parallel development of epithelial tissue.
The etiology of Brodie’s tumor is unclear, so is its pathogenesis. Molecular genetic studies have shown that the carriers of germ line missence-mutation R1699W in the BRCA1 gene have an increased risk of developing malignant Brodie’s tumor, but allele losses at the D22S264 locus of the TP5 gene determine the progression of the disease. Deletion of the short-arm of chromosome 1 (1p) and allelic imbalance are associated with the more aggressive course and recurrences of Brodie’s tumor.
A complex clinicomorphological and molecular genetic study will help answer some questions concerning the diagnosis and treatment of Brodie’s tumors.
About the Authors
D. A. Denchik
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
I. K. Vorotnikov
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
L. N. Lyubchenko
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
O. A. Anurova
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. V. Bykova
Research Institute of Clinical Oncology, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Григорук О.Г., Богатырев В.Н., Лазарев А.Ф. и др. Цитологическая диагностика листовидных опухолей и сарком молочной железы. Маммология 2005;(1):30–2.
2. Воротников И.К., Богатырев В.Н., Корженкова Г.П. Листовидные опухоли и саркомы молочных желез: клиника, диагностика, лечение. Маммология 2006;(1):20–3.
3. Kahan Z., Toszegi A.M., Szarvas F. et al. Recurrent phyllodes tumor in a man. Pathol Res Pract 1997;193(9):653–8.
4. Mallebre B., Ebert A., Perez-Canto A. et al. Cystosarcoma phylloides of the breast. A retrospective analysis of 12 cases. Geburtshilfe Frauenheilkd 1996;56(1):35–40.
5. Draghi F., Sabolla L., Campani R. Diagnostic imaging of phyllodes tumors: preliminary observations. Radiol Med 1996;91(5):585–90.
6. Salvadori B., Cusumano F., Del Bo R. Chirurgia e tumori fillodi deiia mammella. Argomenti Oncol 1990;11(2):157–63.
7. Любченко Л.Н., Портной С.М., Поспехова Н.И. и др. Клинико-молекулярные аспекты наследственного рака молочной железы. Молекул мед 2007;(1):8.
8. Sawyer E., Hanby A., Lakhani S. et al. Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am J Pathol 2000;156(3):1093–8.
9. Wang Z., Buraimoh A., Iglehart J. et al. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphisms array. Breast Cancer Res Treat 2006;97(3):301–9.
10. Rhiem K., Flucke U., Engel C. et al. Associated of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast. Cancer Genet Cytogenet 2007;176:76–9.
Review
For citations:
Denchik D.A., Vorotnikov I.K., Lyubchenko L.N., Anurova O.A., Bykova A.V. Specific features of Brodie’s tumors. Tumors of female reproductive system. 2010;(3):21-23. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-3-21-23
Views:
522
Email this article 